StockTipsArenaBeta

BUY Morepen Laboratories Limited — Chandan Taparia, Motilal Oswal

BUYMorepen Laboratories Limited
Morepen Laboratories share price target & all analyst calls

byChandan Taparia, Motilal OswalHorizon: NA (inferred Swing (≤2wk))1 Oct 2026via Zee Business (Live)

Entry₹133.35Inferred
Target₹150
Total upside +12.49% (call closed)
Stop lossNot given
Exit₹1507 Oct 2026, 9:20 am
Target hit+12.49%0.00%upside left
Follow Chandan Taparia for new calls(36% target hit, 311 closed calls)Get alertsWatch MOREPENLAB for new buy/sell callsGet alertsSee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 7 Oct 2026
4 supporting0 opposing
Supports the BUY call (4)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·1 Oct · 5d ago

Morepen Laboratories promotes Sanjay Suri to MD

NewsGoogle News·30 Sept · 6d ago

(opens in new tab)

Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA, marking a significant step in expanding its integrated CDMO capabilities.

NSE · Press Release·28 Sept · 1w ago

(opens in new tab)

Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Tablets, marking an expansion into integrated finished dosage development.

BSE · Company Update·28 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Morepen Laboratories

All analyst calls on Morepen Laboratories

More from Chandan Taparia, Motilal Oswal

Every call and its outcome